Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis with increased mortality largely attributable to cardiovascular disease. There is extensive evidence that patients with RA experience accelerated atherosclerosis, which is considered as the main responsible of this increased cardiovascular burden. Nowadays atherosclerosis is regarded as an inflammatory condition: hence, the cumulative inflammation of RA, with the abundant synthesis of proinflammatory cytokines, contributes directly to the early formation of the atheromatic plaque. It is therefore reasonable to postulate that, by alleviating inflammation, drugs commonly used in RA treatment may ameliorate the cardiovascular profile of these patients. Here we provide an extensive review of the literature, focusing on the effects of the available anti-rheumatic agents on cardiovascular mortality, and morbidity among RA sufferers.
Keywords: Rheumatoid arthritis, cardiovascular disease, atherosclerosis, inflammation, DMARDs, anti-TNF-α agents, novel biologic agents, atheromatic plaque, AMI, cytokines
Current Vascular Pharmacology
Title:Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis
Volume: 10 Issue: 5
Author(s): Cecilia Chighizola, Tommaso Schioppo, Francesca Ingegnoli and Pier Luigi Meroni
Affiliation:
Keywords: Rheumatoid arthritis, cardiovascular disease, atherosclerosis, inflammation, DMARDs, anti-TNF-α agents, novel biologic agents, atheromatic plaque, AMI, cytokines
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis with increased mortality largely attributable to cardiovascular disease. There is extensive evidence that patients with RA experience accelerated atherosclerosis, which is considered as the main responsible of this increased cardiovascular burden. Nowadays atherosclerosis is regarded as an inflammatory condition: hence, the cumulative inflammation of RA, with the abundant synthesis of proinflammatory cytokines, contributes directly to the early formation of the atheromatic plaque. It is therefore reasonable to postulate that, by alleviating inflammation, drugs commonly used in RA treatment may ameliorate the cardiovascular profile of these patients. Here we provide an extensive review of the literature, focusing on the effects of the available anti-rheumatic agents on cardiovascular mortality, and morbidity among RA sufferers.
Export Options
About this article
Cite this article as:
Chighizola Cecilia, Schioppo Tommaso, Ingegnoli Francesca and Luigi Meroni Pier, Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis, Current Vascular Pharmacology 2012; 10 (5) . https://dx.doi.org/10.2174/157016112801784503
DOI https://dx.doi.org/10.2174/157016112801784503 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modified Pulsincap of Ibuprofen - A Novel Approach for Chronotherapy
Current Drug Delivery Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters UCSF Small Molecule Discovery Center: Innovation, Collaboration and Chemical Biology in the Bay Area
Combinatorial Chemistry & High Throughput Screening Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Editorial [Hot Topic: The Adenosinergic System - From Physiology to Pathology and Therapeutics (Guest Editors: A. Rees and J. Ham)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inhibitory Effect of Selective Cyclooxygenase-2 Inhibitor Etoricoxib on Human Organic Anion Transporter 3 (hOAT3)
Drug Metabolism Letters Zinc-Aceclofenac Complex: Synthesis, Hydrolysis Study and Antiinflammatory Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Subject Index
Current Drug Targets - Inflammation & Allergy Effect of Alpha-1-Acid Glycoprotein Binding on Pharmacokinetics and Pharmacodynamics
Current Drug Metabolism Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Regulation of Neutrophil Apoptosis and Removal of Apoptotic Cells
Current Drug Targets - Inflammation & Allergy Targeting C5a: Recent Advances in Drug Discovery
Current Medicinal Chemistry Pathogenesis in Childhood Idiopathic Nephrotic Syndrome: An Update of Patchwork
Current Pediatric Reviews Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Topical Delivery of Cultured Stem Cells to Human Non-Healing Wounds: GMP Facility Development in an Academic Setting and FDA Requirements for an IND and Human Testing
Current Drug Delivery Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property
Recent Patents on Inflammation & Allergy Drug Discovery New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine